InnoCan Pharma Corporation (CSE:INNO)

Canada flag Canada · Delayed Price · Currency is CAD
0.2100
+0.0200 (10.53%)
Mar 28, 2025, 3:58 PM EST
-34.38%
Market Cap 60.92M
Revenue (ttm) 39.08M
Net Income (ttm) -3.52M
Shares Out 290.12M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 85,849
Average Volume 23,670
Open 0.1900
Previous Close 0.1900
Day's Range 0.1900 - 0.2100
52-Week Range 0.1600 - 0.3300
Beta 2.88
RSI 55.55
Earnings Date Mar 31, 2025

About InnoCan Pharma

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream f... [Read more]

Sector Healthcare
Founded 2018
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol INNO
Full Company Profile

Financial Performance

In 2023, InnoCan Pharma's revenue was $13.66 million, an increase of 433.69% compared to the previous year's $2.56 million. Losses were -$4.70 million, 24.9% more than in 2022.

Financial numbers in USD Financial Statements

News

There is no news available yet.